Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 14, 2021 12:36pm
160 Views
Post# 32297461

RE:RE:RE:RE:RE:RE:RE:Placement

RE:RE:RE:RE:RE:RE:RE:Placement

In case anyone is trying to compare the Unit to the share, the unit costs $2.71 and gets you 1 share worth about $2.59 and a half a warrant worth about $.12.  You should compare the $2.59 they got to the current NASDAQ quote of $2.65 or so.  Right now, the unit is a cheaper way in than the market quote.  No doubt you'll see some quick traders in there post 19th.  You'll also, surprise surprise, see all 3 brokers upgrade and put buys in it.  The upshot is we will likely see for the first time 2 NOV valuations of the pipeline and one wacky 2023 EV/EBITDA multiple valuation or something like that.  Problem is, they've likely sold the units to whatever interested brokers and clients they had but we8ll see.


Greenviolino wrote:

@archeo.

A bought-deal means that the lead broker is writing a check to the company. Therefore the broker is on the hook for any shares that it cannot place. It also explains why the commission on such deals is higher. Give Mackie some credit for having found buyers for the share offering.
The stock is under pressure now because the issue is probably not completely sold yet. Tomorow will be a strong test because settlement of the issue is Jan19. Speculators will sell if they don't make a quick buck. If the stock doesn't move much within the next week, this will tell us that Mackie still has shares to place. So for those complaining they were not contacted to partipate, you have an opportunity to currently buy below issue price in the market. Now, who wants to debate whether this  financing is worse than the convertible debt issue done a couple of years ago? 



<< Previous
Bullboard Posts
Next >>